SNAP-8
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
SNAP-8 is marketed as a longer-chain, “more potent” successor to Argireline (acetyl Hexapeptide-3) within the same neuro-relaxer family of topical “Botox-like” cosmetic peptides.
What does it do in my body?
SNAP-8 inhibits SNARE-complex formation, reducing neurotransmitter release and muscle contraction at the neuromuscular junction — the same target family as the other relaxer peptides in this cluster, aimed at softening expression-line formation.
How can it help me?
- Where the science stands: Anecdotal: 0 studies, 0 human trials on the public profile
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-effect data specific to SNAP-8 was captured in the source profile. As a topical-only ingredient, it carries the family-wide benign safety read — topical delivery, no systemic exposure.
Regulatory status: Sold as a cosmetic-grade topical ingredient — legal OTC, not an FDA-reviewed drug.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
SNAP-8 is a topical-only cosmetic ingredient, typically formulated into serums alongside other neuro-relaxer peptides. No specific concentration figure was captured in the source profile.
What should I avoid combining — and what's synergistic?
SNAP-8 doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
Marketed as a longer, “more potent” successor to Argireline. The mechanism is plausible and the marketing story is clean — but the published evidence for this exact peptide doesn’t yet back it up.
| Class | Neuromuscular “Botox-like” relaxer — topical cosmetic peptide |
| Mechanism (one line) | Inhibits SNARE-complex formation → reduced neurotransmitter release → reduced muscle contraction |
| Evidence base | Anecdotal: 0 studies, 0 human trials on the public profile |
| Safety record | Topical-only; benign safety record (Safety: green) |
| Regulatory status | Cosmetic-grade OTC skincare ingredient, not an FDA-reviewed drug |
What it is
SNAP-8 is marketed as a longer-chain, “more potent” successor to Argireline (acetyl Hexapeptide-3) within the same neuro-relaxer family of topical “Botox-like” cosmetic peptides.
How it works
SNAP-8 inhibits SNARE-complex formation, reducing neurotransmitter release and muscle contraction at the neuromuscular junction — the same target family as the other relaxer peptides in this cluster, aimed at softening expression-line formation.
What the research shows
The public profile grade is Anecdotal: 0 studies, 0 human trials. OHM’s internal 0035 categorization pass keeps SNAP-8 at Tier D / provisional (encyclopedia-only), describing the evidence as “cosmetic-marketing-grade evidence only … no meaningful published RCT base”.
Real-world protocol
SNAP-8 is a topical-only cosmetic ingredient, typically formulated into serums alongside other neuro-relaxer peptides. No specific concentration figure was captured in the source profile.
Side effects & management
No adverse-effect data specific to SNAP-8 was captured in the source profile. As a topical-only ingredient, it carries the family-wide benign safety read — topical delivery, no systemic exposure.
Regulatory status
Sold as a cosmetic-grade topical ingredient — legal OTC, not an FDA-reviewed drug.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier D / provisional (encyclopedia-only).
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Argireline (acetyl Hexapeptide-3) · Vialox · Syn-Ake · Pentapeptide-18
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier D / provisional (encyclopedia-only).
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Argireline (acetyl Hexapeptide-3) · Vialox · Syn-Ake · Pentapeptide-18